Farit A. Khabirov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Farit A. Khabirov has a total of 182 co-authors. Here are the top co-authors by number of shared publications:
- Timur I. Khaybullin
Kazan State Medical Academy, Branch of the Russian Medical Academy for Continuous Professional Education
10 shared publications - Аleksey N. Boyko
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
10 shared publications - Zoya Alexandrovna Goncharova
Rostov State Medical University, Ministry of Health of Russia
8 shared publications - Arina V. Zinkina-Orikhan
BIOCAD
7 shared publications - Elena V. Parshina
Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko
7 shared publications - Evgenii V. Granatov
City Clinical Hospital No. 7
7 shared publications
Latest Publications
- 1 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (2)
Role of disease-modifying drugs in osteoarthritis and pharmaconutraceuticals in the treatment of chronic non-specific back pain
In September 2025, an expert council meeting was held to discuss the role and importance of disease-modifying drugs for osteoarthritis and pharmaconutraceuticals in the treatment of chronic nonspecific back pain. This meeting presented data from studies examining efficacy and safety of bioactive extract and concentrate from small sea fish, chondroitin sulfate, glucosamine and their combinations, as well as some pharmaconutraceuticals in the treatment of musculoskeletal back pain. There is a need to include these agents in clinical guidelines for the management of chronic musculoskeletal back pain for its effective and safe management and prevention.
- 1 July 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (2)
Role of disease-modifying drugs in osteoarthritis and pharmaconutraceuticals in the treatment of chronic non-specific back pain
In September 2025, an expert council meeting was held to discuss the role and importance of disease-modifying drugs for osteoarthritis and pharmaconutraceuticals in the treatment of chronic nonspecific back pain. This meeting presented data from studies examining efficacy and safety of bioactive extract and concentrate from small sea fish, chondroitin sulfate, glucosamine and their combinations, as well as some pharmaconutraceuticals in the treatment of musculoskeletal back pain. There is a need to include these agents in clinical guidelines for the management of chronic musculoskeletal back pain for its effective and safe management and prevention.
- Open Access
- 30 June 2026
- Published by ECO-Vector LLC (Publications) in Annals of Clinical and Experimental Neurology
- Vol. 20 (2) , 26-35
Divozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial
Introduction. Divozilimab, a humanized, afucosylated monoclonal antibody that targets CD20, has been approved to treat multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), and systemic sclerosis. The AQUARELLE clinical trial evaluates the efficacy and safety of divozilimab in patients with NMOSD. Aim. The study aimed to evaluate the efficacy and safety of divozilimab during the first year of treatment in patients with NMOSD. Materials and methods. The AQUARELLE open-label clinical trial enrolled 105 patients with NMOSD. All patients received 500 mg of divozilimab via intravenous infusion every 24 weeks. After 1 year of treatment, the following key parameters were evaluated: the annualized relapse rate (ARR), time to first relapse compared to a historical control group (the placebo group from the SakuraStar study), the proportion of patients with confirmed disability worsening (CDW), changes in Expanded Disability Status Scale (EDSS) scores, and safety parameters. Results. The ARR in patients with NMOSD who received divozilimab for one year was 0.104 (95% confidence interval [CI], 0.056–0.193), and 90.5% of patients had no confirmed relapses. The calculated weighted ratio of ARR (90% CI) for divozilimab to the historical placebo (SAkuraStar) was 0.237 (90% CI: 0.084–0.672), demonstrating superiority of divozilimab. The EDSS score remained stable, and no cases of CDW were reported. Adverse events (AEs) were observed in 76% of patients, most of which were mild or moderate in severity. The most common adverse drug reactions were lymphopenia (21%), leukopenia (11.4%), neutropenia (12.4%), and infusion-related reactions (5.7%). No serious adverse reactions were reported. Conclusion. The 1-year interim results of divozilimab therapy in patients with NMOSD from the AQUARELLE clinical trial demonstrate the sustained efficacy of therapy in reducing both the rate and risk of NMOSD relapses. Additionally, the safety profile was consistent with that expected for anti-B-cell therapy.
- 30 June 2026
- Published by ECO-Vector LLC (Publications) in Annals of Clinical and Experimental Neurology
- Vol. 20 (2) , 26-35
Open AccessDivozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial
Introduction. Divozilimab, a humanized, afucosylated monoclonal antibody that targets CD20, has been approved to treat multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), and systemic sclerosis. The AQUARELLE clinical trial evaluates the efficacy and safety of divozilimab in patients with NMOSD. Aim. The study aimed to evaluate the efficacy and safety of divozilimab during the first year of treatment in patients with NMOSD. Materials and methods. The AQUARELLE open-label clinical trial enrolled 105 patients with NMOSD. All patients received 500 mg of divozilimab via intravenous infusion every 24 weeks. After 1 year of treatment, the following key parameters were evaluated: the annualized relapse rate (ARR), time to first relapse compared to a historical control group (the placebo group from the SakuraStar study), the proportion of patients with confirmed disability worsening (CDW), changes in Expanded Disability Status Scale (EDSS) scores, and safety parameters. Results. The ARR in patients with NMOSD who received divozilimab for one year was 0.104 (95% confidence interval [CI], 0.056–0.193), and 90.5% of patients had no confirmed relapses. The calculated weighted ratio of ARR (90% CI) for divozilimab to the historical placebo (SAkuraStar) was 0.237 (90% CI: 0.084–0.672), demonstrating superiority of divozilimab. The EDSS score remained stable, and no cases of CDW were reported. Adverse events (AEs) were observed in 76% of patients, most of which were mild or moderate in severity. The most common adverse drug reactions were lymphopenia (21%), leukopenia (11.4%), neutropenia (12.4%), and infusion-related reactions (5.7%). No serious adverse reactions were reported. Conclusion. The 1-year interim results of divozilimab therapy in patients with NMOSD from the AQUARELLE clinical trial demonstrate the sustained efficacy of therapy in reducing both the rate and risk of NMOSD relapses. Additionally, the safety profile was consistent with that expected for anti-B-cell therapy.
- Open Access
- 25 May 2026
- Published by ECO-Vector LLC (Publications) in Neurology Bulletin
- Vol. LVIII (2) , 213-220
Early diagnosis of multiple sclerosis in the context of the 2024 McDonald criteria: from clinically and radiologically isolated syndromes to biological verification of the disease
This article examines the evolution of diagnostic criteria for multiple sclerosis (MS), with a focus on the 2024 revision of the McDonald criteria as a milestone in the diagnosis of the disease. A comprehensive analysis of changes in MS diagnostic approaches is presented, demonstrating a shift from reliance on demonstration of dissemination in time (DIT) to confirmation of dissemination in space (DIS) combined with highly specific biological markers. The study describes the search methodology in detail. The final selection included 239 studies after screening and removal of duplicates and irrelevant articles. Practical aspects of implementing the new criteria in clinical practice are discussed, including early-stage diagnosis (clinically and radiologically isolated syndromes), differential diagnosis in special patient groups (children, patients over 50 years of age, and those with cerebrovascular pathology), prospects for early therapy, and medication selection. The 2024 McDonald criteria are shown to improve the accuracy and speed of MS diagnosis, reduce the risk of overdiagnosis, and enable earlier treatment initiation. The need for interdisciplinary collaboration among specialists (neurologists, radiologists, and laboratory diagnosticians) and standardization of research methods to realize the full potential of the updated criteria is emphasized.
- 25 May 2026
- Published by ECO-Vector LLC (Publications) in Neurology Bulletin
- Vol. LVIII (2) , 213-220
Open AccessEarly diagnosis of multiple sclerosis in the context of the 2024 McDonald criteria: from clinically and radiologically isolated syndromes to biological verification of the disease
This article examines the evolution of diagnostic criteria for multiple sclerosis (MS), with a focus on the 2024 revision of the McDonald criteria as a milestone in the diagnosis of the disease. A comprehensive analysis of changes in MS diagnostic approaches is presented, demonstrating a shift from reliance on demonstration of dissemination in time (DIT) to confirmation of dissemination in space (DIS) combined with highly specific biological markers. The study describes the search methodology in detail. The final selection included 239 studies after screening and removal of duplicates and irrelevant articles. Practical aspects of implementing the new criteria in clinical practice are discussed, including early-stage diagnosis (clinically and radiologically isolated syndromes), differential diagnosis in special patient groups (children, patients over 50 years of age, and those with cerebrovascular pathology), prospects for early therapy, and medication selection. The 2024 McDonald criteria are shown to improve the accuracy and speed of MS diagnosis, reduce the risk of overdiagnosis, and enable earlier treatment initiation. The need for interdisciplinary collaboration among specialists (neurologists, radiologists, and laboratory diagnosticians) and standardization of research methods to realize the full potential of the updated criteria is emphasized.
- 22 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 46-54
Differential diagnosis of dizziness and symptomatic therapy
Dizziness is one of the most common reasons for seeking medical attention from specialists in various fields. However, despite its apparent clarity, patients describe a wide range of sensations under this term: from loss of balance and uncertainty when moving to swaying, lightheadedness, pre-syncope, “heaviness in the head”, and coordination problems. Patients often struggle to clearly articulate their complaints and offer several different definitions of their condition. Specifying complaints can be difficult, which complicates diagnosis and determining the cause of dizziness. Therefore, modern practice uses a diagnostic algorithm that includes assessing the nature of vestibular syndrome (acute, intermittent, or persistent), identifying triggering factors, analyzing associated symptoms, performing a physical examination, and, if necessary, additional diagnostic methods. A clinical case study of a patient with multiple sclerosis who initially presented with complaints of dizziness illustrates the complexity of diagnosing this condition. In the treatment of dizziness, the primary goal is rapid and effective symptom relief. Given the frequent presence of comorbidities requiring the simultaneous use of multiple medications, combination medications are preferred. One such drug is the fixed-dose combination of dimenhydrinate 40 mg and cinnarizine 20 mg (Arlevert). Low doses of dimenhydrinate and cinnarizine enhance each other’s effects when used together, with minimal adverse effects. Due to the different mechanisms and locations of action of the components (peripheral action of cinnarizine and central action of dimenhydrinate), Arlevert is the only anti-dizzy medication with synergistic action in both peripheral and central areas.
- 22 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 46-54
Differential diagnosis of dizziness and symptomatic therapy
Dizziness is one of the most common reasons for seeking medical attention from specialists in various fields. However, despite its apparent clarity, patients describe a wide range of sensations under this term: from loss of balance and uncertainty when moving to swaying, lightheadedness, pre-syncope, “heaviness in the head”, and coordination problems. Patients often struggle to clearly articulate their complaints and offer several different definitions of their condition. Specifying complaints can be difficult, which complicates diagnosis and determining the cause of dizziness. Therefore, modern practice uses a diagnostic algorithm that includes assessing the nature of vestibular syndrome (acute, intermittent, or persistent), identifying triggering factors, analyzing associated symptoms, performing a physical examination, and, if necessary, additional diagnostic methods. A clinical case study of a patient with multiple sclerosis who initially presented with complaints of dizziness illustrates the complexity of diagnosing this condition. In the treatment of dizziness, the primary goal is rapid and effective symptom relief. Given the frequent presence of comorbidities requiring the simultaneous use of multiple medications, combination medications are preferred. One such drug is the fixed-dose combination of dimenhydrinate 40 mg and cinnarizine 20 mg (Arlevert). Low doses of dimenhydrinate and cinnarizine enhance each other’s effects when used together, with minimal adverse effects. Due to the different mechanisms and locations of action of the components (peripheral action of cinnarizine and central action of dimenhydrinate), Arlevert is the only anti-dizzy medication with synergistic action in both peripheral and central areas.
- Open Access
- 23 August 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 16-25
Divozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders
Objective: the aim of the AQUARELLE trial was to evaluate the efficacy of divozilimab compared with a historical control (placebo) and to characterise its safety in patients with neuromyelitis optica spectrum disorder (NMOSD).Material and methods. The AQUARELLE clinical trial population included patients aged 18 years and older with a diagnosis of NMOSD established in accordance with the international consensus diagnostic criteria for NMOSD (2015). The primary efficacy endpoint was the mean annual rate of confirmed exacerbations (MAR) over 6 months of treatment with divozilimab compared with a historical control, which was the placebo from the N-MOmentum study.Results. A total of 105 patients received treatment with the investigational drug divozilimab. At the time of analysis, the proportion of patients without confirmed exacerbations was 94.3% (99/105); the ARR was 0.124 (95% CI 0.056–0.276). The ARR ratio for divozilimab /historical placebo was 0.172 (90% CI 0,083–0,359), indicating the superiority of divozilimab compared to historical placebo over 6 months of therapy. During divozilimab therapy, a therapy-related decrease in lymphocyte count was reported in 16 (15.2%) patients, and infusion reactions were reported in 6 (5.7%) patients. The overall incidence of therapy-related infectious events was 6 cases (5.7%).Conclusion. Within patients with NMOSD, the use of divozilimab reduces the risk of exacerbations. The good tolerability of the drug allows divozilimab to be recommended as a new therapeutic option for patients with NMOSD.
- 23 August 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 16-25
Open AccessDivozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders
Objective: the aim of the AQUARELLE trial was to evaluate the efficacy of divozilimab compared with a historical control (placebo) and to characterise its safety in patients with neuromyelitis optica spectrum disorder (NMOSD).Material and methods. The AQUARELLE clinical trial population included patients aged 18 years and older with a diagnosis of NMOSD established in accordance with the international consensus diagnostic criteria for NMOSD (2015). The primary efficacy endpoint was the mean annual rate of confirmed exacerbations (MAR) over 6 months of treatment with divozilimab compared with a historical control, which was the placebo from the N-MOmentum study.Results. A total of 105 patients received treatment with the investigational drug divozilimab. At the time of analysis, the proportion of patients without confirmed exacerbations was 94.3% (99/105); the ARR was 0.124 (95% CI 0.056–0.276). The ARR ratio for divozilimab /historical placebo was 0.172 (90% CI 0,083–0,359), indicating the superiority of divozilimab compared to historical placebo over 6 months of therapy. During divozilimab therapy, a therapy-related decrease in lymphocyte count was reported in 16 (15.2%) patients, and infusion reactions were reported in 6 (5.7%) patients. The overall incidence of therapy-related infectious events was 6 cases (5.7%).Conclusion. Within patients with NMOSD, the use of divozilimab reduces the risk of exacerbations. The good tolerability of the drug allows divozilimab to be recommended as a new therapeutic option for patients with NMOSD.
- 8 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 39-44
Features of the clinical course of multiple sclerosis as a factor in persistent disability
Objective. To study the effect of clinical factors on the disability of multiple sclerosis (MS) patients based on the data from the Republic of Tatarstan. Materials and methods. The study was based on the patient data from the regional register of patients with MS of the Republic of Tatarstan maintained at the Republican Clinical Diagnostic Center for Demyelinating Diseases of the Ministry of Health of the Republic of Tatarstan. Of the 2.673 patients with a confirmed MS diagnosis, 749 (28.0%) had disabilities, including 299 (11.2%) with disability group III, 267 (10.0%) with disability group II, and 183 (6.8%) with disability group I. Results. It has been established that the disability of MS patients depends on various clinical factors, such as the nosological form of MS, onset variants, values of the Extended Disability Rating Scale (EDSS) at the time of inclusion in the register, and the availability of treatment with multiple sclerosis disease-modifying drugs (MSDMD). Patients with secondary-progressive or primary-progressive MS, with slight symptoms at the onset of the disease, not receiving MSDMD treatment, and with baseline EDSS scores over 3 at the time of inclusion in the register have a higher risk of disability. Conclusion. The obtained results demonstrate the importance of timely access to medical care and specific treatment for patients with MS to preserve their working capacity and active life and significantly delay severe health disorders. The persistent nature of disability in patients with MS and the high rate of disability in patients (more than ¼ of those with MS) indicates the relevance of further study of the factors influencing the occurrence and development of disability in this group of patients.
- 8 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 39-44
Features of the clinical course of multiple sclerosis as a factor in persistent disability
Objective. To study the effect of clinical factors on the disability of multiple sclerosis (MS) patients based on the data from the Republic of Tatarstan. Materials and methods. The study was based on the patient data from the regional register of patients with MS of the Republic of Tatarstan maintained at the Republican Clinical Diagnostic Center for Demyelinating Diseases of the Ministry of Health of the Republic of Tatarstan. Of the 2.673 patients with a confirmed MS diagnosis, 749 (28.0%) had disabilities, including 299 (11.2%) with disability group III, 267 (10.0%) with disability group II, and 183 (6.8%) with disability group I. Results. It has been established that the disability of MS patients depends on various clinical factors, such as the nosological form of MS, onset variants, values of the Extended Disability Rating Scale (EDSS) at the time of inclusion in the register, and the availability of treatment with multiple sclerosis disease-modifying drugs (MSDMD). Patients with secondary-progressive or primary-progressive MS, with slight symptoms at the onset of the disease, not receiving MSDMD treatment, and with baseline EDSS scores over 3 at the time of inclusion in the register have a higher risk of disability. Conclusion. The obtained results demonstrate the importance of timely access to medical care and specific treatment for patients with MS to preserve their working capacity and active life and significantly delay severe health disorders. The persistent nature of disability in patients with MS and the high rate of disability in patients (more than ¼ of those with MS) indicates the relevance of further study of the factors influencing the occurrence and development of disability in this group of patients.
- Open Access
- 12 April 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 71-80
Diagnosis and therapy of cognitive impairment in chronic cerebral ischemia
Chronic cerebral ischemia is a common condition associated with progressive brain damage that manifests itself in various neurological disorders, including cognitive impairment. One of the etiologic factors of vascular disorders is arterial hypertension. The article discusses types of cognitive impairment and pathogenetic mechanisms of their formation. The role of the glymphatic system of the brain, the role of neuroinflammation in the implementation of cognitive impairment are discussed. The described clinical case shows the need to supplement basic therapy in patients with hypertension with drugs of other groups, in particular pentoxifylline, to improve the effectiveness of therapy. The article reviews the latest clinical and experimental studies of pentoxifylline, which show its positive effect on inflammation, endothelial dysfunction and, as a result, improvement of cognitive functions. The neuroprotective effect of pentoxifylline, which has been confirmed in experimental and clinical studies, is discussed. The possibility of using pentoxifylline in patients with mood disorders, major depressive disorder, bipolar disorder as an adjunct to the main therapy, and in cognitive impairment as monotherapy is discussed.
- 12 April 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 71-80
Open AccessDiagnosis and therapy of cognitive impairment in chronic cerebral ischemia
Chronic cerebral ischemia is a common condition associated with progressive brain damage that manifests itself in various neurological disorders, including cognitive impairment. One of the etiologic factors of vascular disorders is arterial hypertension. The article discusses types of cognitive impairment and pathogenetic mechanisms of their formation. The role of the glymphatic system of the brain, the role of neuroinflammation in the implementation of cognitive impairment are discussed. The described clinical case shows the need to supplement basic therapy in patients with hypertension with drugs of other groups, in particular pentoxifylline, to improve the effectiveness of therapy. The article reviews the latest clinical and experimental studies of pentoxifylline, which show its positive effect on inflammation, endothelial dysfunction and, as a result, improvement of cognitive functions. The neuroprotective effect of pentoxifylline, which has been confirmed in experimental and clinical studies, is discussed. The possibility of using pentoxifylline in patients with mood disorders, major depressive disorder, bipolar disorder as an adjunct to the main therapy, and in cognitive impairment as monotherapy is discussed.
- 13 March 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (1)
Resolution of the Council of Experts on the Treatment of Radiculopathy “New approaches to the treatment of back pain”
On November 08, 2024 in Moscow, under the auspices of the Russian Society for the Study of Pain (RSSP), a Council of Experts was held, during which leading specialists in the field of neurology, who have a high level of expertise in the treatment of back pain, discussed modern approaches to the therapy of discogenic lumbosacral radiculopathy (DLSR). The Council actualized the leading pathogenetic mechanisms of the disease onset and progression; discussed the mechanisms of pathogenesis, which are currently still insufficiently affected by pharmacotherapeutic intervention. Conservative therapy of DLSR is effective and allows to avoid surgical treatment in the majority (more than 90%) of cases. The leading role in conservative therapy of DLSR is played by informing the patient about the benign nature of DLSR, the possibility of spontaneous regression of disc herniation, methods of kinesiotherapy under the supervision of a specialist, epidural administration of local anesthetics and glucocorticoids in the acute period of the disease. In real practice, non-steroidal anti-inflammatory drugs, anticonvulsants are widely used, but their effectiveness remains controversial, so the search for new methods of conservative therapy is relevant. The experts noted the importance of the approach to the treatment of the problem under consideration from the position of its pathogenesis and discussed the introduction of new groups of drugs, emphasizing the need to expand clinical recommendations in favor of drugs with pathogenetically justified and complex mechanisms of action in back pain. The results of RCTs and the experience of clinical application of parenteral preparation of triterpene saponin escin — L-lysine escinate in different groups of patients with DLSR were discussed in detail. The expediency of conducting a multicenter placebo-controlled study of the efficacy of escin — L-lysine escinate in acute DLSR was noted.
- 13 March 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (1)
Resolution of the Council of Experts on the Treatment of Radiculopathy “New approaches to the treatment of back pain”
On November 08, 2024 in Moscow, under the auspices of the Russian Society for the Study of Pain (RSSP), a Council of Experts was held, during which leading specialists in the field of neurology, who have a high level of expertise in the treatment of back pain, discussed modern approaches to the therapy of discogenic lumbosacral radiculopathy (DLSR). The Council actualized the leading pathogenetic mechanisms of the disease onset and progression; discussed the mechanisms of pathogenesis, which are currently still insufficiently affected by pharmacotherapeutic intervention. Conservative therapy of DLSR is effective and allows to avoid surgical treatment in the majority (more than 90%) of cases. The leading role in conservative therapy of DLSR is played by informing the patient about the benign nature of DLSR, the possibility of spontaneous regression of disc herniation, methods of kinesiotherapy under the supervision of a specialist, epidural administration of local anesthetics and glucocorticoids in the acute period of the disease. In real practice, non-steroidal anti-inflammatory drugs, anticonvulsants are widely used, but their effectiveness remains controversial, so the search for new methods of conservative therapy is relevant. The experts noted the importance of the approach to the treatment of the problem under consideration from the position of its pathogenesis and discussed the introduction of new groups of drugs, emphasizing the need to expand clinical recommendations in favor of drugs with pathogenetically justified and complex mechanisms of action in back pain. The results of RCTs and the experience of clinical application of parenteral preparation of triterpene saponin escin — L-lysine escinate in different groups of patients with DLSR were discussed in detail. The expediency of conducting a multicenter placebo-controlled study of the efficacy of escin — L-lysine escinate in acute DLSR was noted.
- Open Access
- 14 August 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 101-107
Early use of cladribine tablets for relapsing-remitting multiple sclerosis: Expert opinion
In March 2020, oral cladribine was licensed in Russian Federation for the treatment of adult patients with highly active relapsing multiple sclerosis as defined by clinical or imaging features. Three years after the introduction into the Russian market, practical aspects in the use of cladribine tablets we evaluated, including data from real-world studies and the experience gained in the own routine clinical practice. Early initiation of cladribine therapy, use of cladribine in treatment naïve patients and patients with suboptimal response to previous disease-modifying therapy, use of cladribine as the treatment of choice in patients with suboptimal response to platform disease-modifying therapy and washout period while switching to cladribine from other disease-modifying therapy. During the discussion thirteen neurologists from federal and regional centers experienced in multiple sclerosis diagnosis and therapy were asked to answer several questions regarding the practical use of cladribine tables and come to consensus opinion. Consent was reached if at least 75% of the experts agreed on a particular statement. The experts agreed on the possibility to switch patients to cladribine from platform disease-modifying therapy in case of MRI activity or neutralizing antibodies in the absence of relapses activity to achieve better disease control, potential cladribine effects on progression independent of relapses, washout period reduction while switching from natalizumab to cladribine. Consensus opinion will help to manage practical questions regarding cladribine usage.
- 14 August 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 101-107
Open AccessEarly use of cladribine tablets for relapsing-remitting multiple sclerosis: Expert opinion
In March 2020, oral cladribine was licensed in Russian Federation for the treatment of adult patients with highly active relapsing multiple sclerosis as defined by clinical or imaging features. Three years after the introduction into the Russian market, practical aspects in the use of cladribine tablets we evaluated, including data from real-world studies and the experience gained in the own routine clinical practice. Early initiation of cladribine therapy, use of cladribine in treatment naïve patients and patients with suboptimal response to previous disease-modifying therapy, use of cladribine as the treatment of choice in patients with suboptimal response to platform disease-modifying therapy and washout period while switching to cladribine from other disease-modifying therapy. During the discussion thirteen neurologists from federal and regional centers experienced in multiple sclerosis diagnosis and therapy were asked to answer several questions regarding the practical use of cladribine tables and come to consensus opinion. Consent was reached if at least 75% of the experts agreed on a particular statement. The experts agreed on the possibility to switch patients to cladribine from platform disease-modifying therapy in case of MRI activity or neutralizing antibodies in the absence of relapses activity to achieve better disease control, potential cladribine effects on progression independent of relapses, washout period reduction while switching from natalizumab to cladribine. Consensus opinion will help to manage practical questions regarding cladribine usage.
- Open Access
- 7 August 2024
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 16, 44-50
Experience with the use of cladribine tablets in real-life clinical practice: independent analysis of data from 12 Russian clinical centres
Multiple sclerosis (MS) is an autoimmune-inflammatory and neurodegenerative disease of the central nervous system. The article analyses the ability of cladribine, which due to its selective lymphotoxic effect on activated cells and central effect on immunomodulation in brain tissue underwent successful clinical trials in 2010, when it was (temporarily) approved in Russia.Objective: to analyse the effect of cladribine tablets in daily practice on the course of MS over 3–4 year observational period after immune reconstitution therapy (IRT) in several neurological clinics from different regions of Russia.Material and methods. We collected data on 235 patients from 12 neurological clinics and regional MS centres who were followed for an average of 3.4 years after starting cladribine treatment.Results. An independent analysis of cases in which cladribine tablets were prescribed showed that the reason for prescribing cladribine was highly active MS (HARS) in 159 (67.7%) patients, rapidly progressive MS (RPMS) in 20 (8.5%), active relapsing-remitting MS – in 50 (21.3%) and secondary progressive MS with exacerbations – in 6 (2.5%). Only 12 (5.1%) of these patients had not previously received disease-modifying therapies (DMTs), i.e. in these cases the drug was the first DMT prescribed. Among patients who had received a second-line DMTs before switching to cladribine, 22 had previously received natalizumab, 5 had received ocrelizumab and only 1 had received fingolimod. Remaining patients (n=195) were switched from first-line DMTs. In all cases, a decrease in the frequency of exacerbations was observed during and after completion of the IRT course. Exacerbations between the first and second course of cladribine were observed in 36 patients (15.3% of all treated patients), including in almost half of the cases those who were switched from natalizumab (17 exacerbations or 47.2% of all exacerbations, that developed between the first and second course of therapy) and in three cases – from ocrelizumab (8.3 % of exacerbations that developed between the first and second course of therapy, or 60 % of all those switched from ocrelizumab to cladribine). After completion of full cladribine treatment during the four-year observation period, exacerbations occurred in 14 patients (6% of all patients included in the analysis), six of which occurred after switching from natalizumab.Conclusion. The results are generally consistent with the results of recently published meta-analyses and reviews, but the high likelihood of exacerbations in patients switched from second-line therapies such as natalizumab and ocrelizumab is noteworthy. Both drugs are prescribed for aggressive types of MS with exacerbations (highly active and rapidly progressive) who had a high frequency of exacerbations and an increase in Expanded Disability Status Scale (EDSS) scores prior to being prescribed these drugs. The switch from natalizumab is usually due to an increased risk of developing progressive multifocal encephalopathy with a high titre of antibodies against the JC-virus and the duration of natal izumab use of more than 2 years. It is likely that the resumption of MS activity after discontinuation of natalizumab is quite pronounced, and replacement with treatment with cladribine in tablet form is not able to completely prevent this. In this respect, such a switch does not appear to be optimal, in contrast to cases where first-line drugs are switched to cladribine.
- 7 August 2024
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 16, 44-50
Open AccessExperience with the use of cladribine tablets in real-life clinical practice: independent analysis of data from 12 Russian clinical centres
Multiple sclerosis (MS) is an autoimmune-inflammatory and neurodegenerative disease of the central nervous system. The article analyses the ability of cladribine, which due to its selective lymphotoxic effect on activated cells and central effect on immunomodulation in brain tissue underwent successful clinical trials in 2010, when it was (temporarily) approved in Russia.Objective: to analyse the effect of cladribine tablets in daily practice on the course of MS over 3–4 year observational period after immune reconstitution therapy (IRT) in several neurological clinics from different regions of Russia.Material and methods. We collected data on 235 patients from 12 neurological clinics and regional MS centres who were followed for an average of 3.4 years after starting cladribine treatment.Results. An independent analysis of cases in which cladribine tablets were prescribed showed that the reason for prescribing cladribine was highly active MS (HARS) in 159 (67.7%) patients, rapidly progressive MS (RPMS) in 20 (8.5%), active relapsing-remitting MS – in 50 (21.3%) and secondary progressive MS with exacerbations – in 6 (2.5%). Only 12 (5.1%) of these patients had not previously received disease-modifying therapies (DMTs), i.e. in these cases the drug was the first DMT prescribed. Among patients who had received a second-line DMTs before switching to cladribine, 22 had previously received natalizumab, 5 had received ocrelizumab and only 1 had received fingolimod. Remaining patients (n=195) were switched from first-line DMTs. In all cases, a decrease in the frequency of exacerbations was observed during and after completion of the IRT course. Exacerbations between the first and second course of cladribine were observed in 36 patients (15.3% of all treated patients), including in almost half of the cases those who were switched from natalizumab (17 exacerbations or 47.2% of all exacerbations, that developed between the first and second course of therapy) and in three cases – from ocrelizumab (8.3 % of exacerbations that developed between the first and second course of therapy, or 60 % of all those switched from ocrelizumab to cladribine). After completion of full cladribine treatment during the four-year observation period, exacerbations occurred in 14 patients (6% of all patients included in the analysis), six of which occurred after switching from natalizumab.Conclusion. The results are generally consistent with the results of recently published meta-analyses and reviews, but the high likelihood of exacerbations in patients switched from second-line therapies such as natalizumab and ocrelizumab is noteworthy. Both drugs are prescribed for aggressive types of MS with exacerbations (highly active and rapidly progressive) who had a high frequency of exacerbations and an increase in Expanded Disability Status Scale (EDSS) scores prior to being prescribed these drugs. The switch from natalizumab is usually due to an increased risk of developing progressive multifocal encephalopathy with a high titre of antibodies against the JC-virus and the duration of natal izumab use of more than 2 years. It is likely that the resumption of MS activity after discontinuation of natalizumab is quite pronounced, and replacement with treatment with cladribine in tablet form is not able to completely prevent this. In this respect, such a switch does not appear to be optimal, in contrast to cases where first-line drugs are switched to cladribine.